Market evolution: Blood fractions (CN 300212) — 2015–2025

Introduction

Antisera and other blood fractions (CN 300212) encompass immunoglobulins, albumin, and other plasma-derived therapeutic products used in immunology, oncology, and critical care. This product group sits at the intersection of pharmaceutical manufacturing and biological raw-material sourcing, making its trade patterns especially sensitive to regulatory, epidemiological, and geopolitical shifts. The European Union occupies a central role in global trade for this code: it is simultaneously a major producer, a large exporter, and a significant importer. This report examines EU extra-Union trade in CN 300212 over the period 2017–2025 — the years for which complete annual data are available — and identifies the principal structural dynamics shaping this market. All figures are drawn from the General Overview dashboard unless otherwise noted.

1. A Rising-Value, Shrinking-Volume Market

The headline story of EU trade in blood fractions over 2017–2025 is a striking divergence between value and volume, particularly on the export side. While the monetary worth of trade has surged, physical quantities have moved in opposite directions for exports versus imports, pointing to a structural upshift in product mix and pricing.

1.1 Export value rose 46 % while tonnage fell 19 %

Between 2017 and 2025, EU exports of blood fractions grew from €8.9 billion to €13.0 billion (+46.1 %). Over the same period, export volume declined from 21,462 tonnes to 17,318 tonnes (−19.3 %). The reconciliation lies in unit prices: the average export price climbed from €415,408 per tonne to €752,018 per tonne (+81.0 %), reaching its peak in 2025.

Source: General Overview

This pattern is consistent with a product mix shifting toward higher-value, lower-volume biologics — such as specialised monoclonal antibodies and purified immunoglobulin preparations — and away from commodity plasma fractions. It also reflects broader pharmaceutical pricing trends and the growing clinical demand for targeted immunological therapies.

1.2 Import value grew even faster, driven by both volume and price

Imports tell a different story. EU import value rose from €5.0 billion to €8.6 billion (+74.6 %), but unlike exports, volume also expanded substantially — from 21,950 tonnes to 31,135 tonnes (+41.8 %). Import unit prices increased more modestly, from €225,345 to €277,589 per tonne (+23.2 %).

Source: General Overview

The fact that import volumes grew while export volumes shrank indicates that EU-based manufacturers are increasingly sourcing raw or semi-processed plasma fractions from abroad for higher-value-added processing domestically. The widening price gap between exports (€752,018/t) and imports (€277,589/t) — roughly a 2.7:1 ratio in 2025 — underscores the EU's role as a high-value processing hub that imports lower-cost inputs and exports premium finished products.

1.3 The EU's trade surplus widened, but import dependence grew in volume terms

The EU maintained a positive trade balance throughout the period, rising from €3.97 billion in 2017 to €4.38 billion in 2025 (+10.5 %). However, this masks a nuanced shift: while the value surplus held, the volume balance deteriorated, as import tonnage grew nearly 42 % while export tonnage fell 19 %. The net import reliance metric remained deeply negative (from −165 % to −537 %), confirming that the EU is structurally a net exporter by value, and increasingly so. Yet growing physical import volumes signal that the bloc's manufacturing base depends ever more heavily on inbound plasma and crude fractions.

2. Transatlantic Dominance and Deepening Partner Concentration

The geographic structure of EU trade in blood fractions is dominated by a small number of partners, with the United States playing an outsized and growing role. Import-side concentration has risen sharply, creating a more asymmetric trade landscape.

2.1 The United States consolidated its position as the EU's primary supplier

The United States was already the EU's largest source of blood-fraction imports in 2017 (€3.1 billion), but by 2025 that figure had more than doubled to €6.5 billion (+110.7 %). The US accounted for roughly three-quarters of total EU imports by value in the final year. No other partner came close: Switzerland, the second-largest supplier, remained essentially flat at €1.5 billion (+3.1 %), while the United Kingdom actually declined (−22.6 %).

Source: By-country partners

The growing US share reflects the structure of the global plasma industry: major US-based plasma collectors (e.g., CSL Behring's US operations, Takeda's BioLife network) supply fractionated intermediates to European processors. The concentration of raw plasma sourcing in the US — where paid-donor collection is legally permitted at scale — creates a structural dependency for the EU.

2.2 Import concentration (HHI) rose 25 %, signalling growing supply-side risk

The Herfindahl-Hirschman Index for import concentration by value climbed from 4,813 in 2017 to 6,029 in 2025 (+25.3 %), reaching its highest level in the entire period. Import concentration by volume also rose, from 6,103 to 6,875 (+12.6 %). By contrast, export concentration remained moderate and slightly declining (HHI by value fell from 1,972 to 1,899, −3.7 %), indicating that EU exports are distributed across a broader set of destinations.

Source: Concentration dashboard

An HHI above 2,500 is typically considered "highly concentrated." The import-side HHI of 6,029 implies that the EU's inbound supply chain for blood fractions is exceptionally concentrated, dominated overwhelmingly by the United States. This creates vulnerability to any disruption — regulatory, logistical, or geopolitical — affecting US-EU plasma flows.

2.3 Export destinations diversified, led by rapid growth in China

While import sources became more concentrated, EU export destinations showed modest diversification. Switzerland remained the top destination (€2.6 billion, +18.6 %), followed by the United States (€4.2 billion, +38.7 %). The most dramatic growth, however, was in exports to China, which surged from €496 million to €1.18 billion (+138.2 %). Other emerging destinations included Viet Nam (+62.3 %) and the United Kingdom (+28.6 %).

Source: By-country partners

China's rapid absorption of EU blood-fraction exports likely reflects rising domestic demand for immunoglobulin therapies, limited local fractionation capacity, and China's post-COVID emphasis on securing biologic supply chains. Meanwhile, exports to Russia contracted 13.6 %, potentially reflecting the impact of sanctions and supply-chain rerouting following 2022.

2.4 Germany, Austria, and Denmark drove intra-EU export growth

Among EU member states, Germany remained the largest exporter of blood fractions (€5.1 billion in 2025, +82.1 % from 2017), followed by Ireland (€2.3 billion, +3.2 %) and Austria (€2.3 billion, +155.1 %). Denmark's export growth was particularly striking, surging from €226 million to €1.16 billion (+411.2 %), likely reflecting the expansion of Novo Nordisk's and other Danish biopharma firms' international sales of fractionated products.

On the import side, Germany (€3.3 billion, +90.1 %) and Austria (€1.8 billion, +152.5 %) absorbed the largest shares, consistent with their roles as major processing hubs that import crude fractions for domestic value-added production.

Source: By-country reporters

3. A Structurally Resilient Sector with Emerging Price-Instability Risks

Despite the EU's strong net-exporter position and expanding production base, the data reveal pockets of price volatility and supply-side vulnerability that merit attention.

3.1 EU production value expanded 65 %, confirming sectoral growth

EU domestic production of blood fractions — as captured by the PRODCOM mapping to code 21.20.21.26 — grew from €29.2 billion to €48.2 billion (+65.0 %) over the available window. This confirms that the trade trends observed above are embedded in a genuine expansion of the EU's manufacturing base, not merely a reclassification or re-export dynamic.

Source: Production volumes

The specialisation data for 2025 confirm the expected geography: Austria (RSCA 0.75, RCA 6.96) and Ireland (RSCA 0.45, RCA 2.66) are the most specialised EU producers, with Sweden also showing strong specialisation (RSCA 0.59). By contrast, Romania, Portugal, and Poland show negligible specialisation in this product group.

3.2 Export-price shocks were frequent and severe, especially vis-à-vis the United States

The volatility analysis reveals that export-price instability was concentrated in a small number of bilateral relationships. The most extreme shock detected was a 129.3 % surge in EU export prices to the United States in 2019, with an abnormality score of 932.4 — the highest in the dataset. This event, representing 39.9 % of total export value, likely reflects either a compositional shift toward premium biologics or a one-off price spike linked to supply tightness or contract renegotiations.

Source: Supply shocks

Chile experienced a 2,502.7 % price spike in 2022, though its share of total export value was negligible (0.2 %). The UK shock in 2021 (+138.8 %) is more consequential given the UK's 6 % value share and may reflect post-Brexit trade-friction effects on pricing.

3.3 Import-side volatility is moderate overall, but a few partners carry outsized risk

Import-price volatility was generally lower than on the export side, with most major partners showing coefficient-of-variation (CV) values below 0.5. The key exceptions were Australia (CV 0.76) and, outside the top partners, Türkiye (CV 1.70) and Egypt (CV 1.50). While these latter partners represent small shares of EU import value, their extreme volatility suggests unreliable supply that could become problematic if the EU sought to diversify away from US dependence.

Source: Volatility bars

3.4 The EU's export propensity declined, suggesting a maturing domestic market

The export propensity — exports as a share of production — fell from 218.7 % to 178.7 % (−18.3 %), while trade intensity (total trade as a share of production) declined from 155.7 % to 140.5 % (−9.8 %). Both ratios remained well above 100 %, indicating that the EU continues to trade significantly more than it produces domestically in volume terms — consistent with a hub-and-spoke model where raw materials are imported, processed, and re-exported.

The declining export propensity suggests that a growing share of EU production is being absorbed by the domestic market, potentially reflecting expanding healthcare demand within the EU for immunoglobulin and albumin therapies. Alternatively, it may indicate that some EU member states are building fractionation capacity for domestic consumption rather than export.

Conclusion

EU trade in blood fractions (CN 300212) over 2017–2025 reveals a sector that has grown substantially in value (exports +46 %, imports +75 %) while undergoing important structural shifts. The EU remains a powerful net exporter by value, with a trade surplus of €4.4 billion in 2025, supported by a domestic production base that expanded 65 % to €48 billion. However, three risks stand out.

First, the EU's import supply chain has become dangerously concentrated: the United States now accounts for roughly three-quarters of inbound value, and the import-side HHI has risen to 6,029. Any disruption to US-EU plasma flows — whether from regulatory divergence, trade policy, or pandemic-related collection shortfalls — would ripple through the European biopharmaceutical sector.

Second, export-price volatility remains elevated in key bilateral relationships, particularly with the United States and the United Kingdom. The 2019 US price shock (an abnormality score of 932.4) demonstrates that even the largest trade flows are susceptible to sudden pricing dislocations.

Third, the divergence between rising export prices and falling export volumes suggests a product-mix shift toward premium biologics. While this is positive for value capture, it also implies greater reliance on sophisticated manufacturing processes and regulatory pathways — areas where competitive pressure from emerging markets (notably China, which is rapidly expanding its absorption of EU exports) could intensify.

In sum, the EU's blood-fraction trade position is strong but increasingly asymmetric: it depends on US-supplied raw materials and exports high-value finished products to a diversifying but still concentrated set of markets. Policymakers concerned with biopharmaceutical sovereignty should monitor both the concentration of inbound supply and the price stability of outbound flows.